Compare Amgen, Inc. (AMGN) vs SPDR Gold Trust (GLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs SPDR Gold Trust — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while SPDR Gold Trust trades at $373.34. The key difference: Amgen, Inc. pays a 2.77% dividend while SPDR Gold Trust pays none, and Amgen, Inc. is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| AMGN | GLD | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $495.90 |
52-Week Low | $271.18 | $300.96 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GLD trades at $376.91, down 0.34% on the day, with a bearish technical signal driven by moving averages. The stock lacks standard financial ratios (P/E, P/S, P/B, ROE) as it is an ETF tracking gold. Recent news highlights gold's 25% decline from highs, central bank buying support, and mixed sentiment ahead of CPI data and Federal Reserve policy cues, keeping prices range-bound near $4,100/oz equivalents.
Outlook hinges on macroeconomic factors: inflation data and Fed policy may test support levels, while geopolitical risks and central bank demand provide buffers. Risks include prolonged rate hikes pressuring gold, but long-term bullish fundamentals persist. Investors face volatility with no clear near-term catalyst for breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
